Premium
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease
Author(s) -
Hindryckx Pieter,
Novak Gregor,
Bonovas Stefanos,
PeyrinBiroulet Laurent,
Danese Silvio
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.791
Subject(s) - medicine , inflammatory bowel disease , ulcerative colitis , inflammatory bowel diseases , disease , tuberculosis , crohn's disease , biologic agents , intensive care medicine , immunology , pathology
The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).